BWX Technologies二季度小幅盈利超预期但收入略低于预期，上调全年指引后盘后仍下跌

Trump insists Iran talks ongoing, says Hormuz could open ’literally by tomorrow’
Introduction & Market Context
BWX Technologies (NYSE:BWXT) presented second-quarter 2026 results on August 3 that showcased accelerating commercial nuclear growth and prompted the company to raise its full-year outlook, even as shares slipped in after-hours trading following a modest revenue miss against Wall Street expectations. The nuclear components and services supplier reported adjusted earnings of $1.07 per share, beating the $1.05 consensus, while revenue of $901.6 million came in slightly below the $905.4 million forecast.
Despite the earnings beat, shares fell 3.23% to $168.18 in after-hours trading after closing the regular session up 3.02% at $173.79. The after-hours decline suggested investors focused on the small revenue shortfall and higher planned capital spending rather than the company’s improved outlook and 40% year-over-year backlog growth to $8.4 billion.
Quarterly Performance Highlights
The company’s second-quarter results reflected divergent performance between its two main business segments, with commercial operations delivering exceptional growth while government operations posted more modest gains.
As shown in the following financial summary, BWXT’s overall revenue increased 18% year-over-year to $902 million, with organic growth of 9% excluding acquisitions.
Total adjusted EBITDA rose 7% to $155 million, though the margin compressed to 17.2% from 19.1% in the prior-year period due to business mix shifts and higher corporate expenses. Non-GAAP earnings per share increased 5% to $1.07, driven by higher operating income and lower interest expense, partially offset by reduced other income and a higher tax rate. Free cash flow came in at $115 million for the quarter.
The following bridge analysis illustrates the key drivers behind the earnings per share improvement from $1.02 in Q2 2025 to $1.07 in Q2 2026.
Operations contributed $0.05 to the EPS increase, with positive impacts from both Government and Commercial revenue growth and improved Commercial margins, partially offset by lower Government margins and higher corporate expenses. Lower interest expense added $0.09 due to balance sheet optimization, while non-operational headwinds from pension and other income items reduced EPS by $0.06, and a higher tax rate subtracted another $0.03.
Segment Performance Analysis
The company’s two operating segments showed markedly different growth trajectories during the quarter, as illustrated in the following segment breakdown.
Government Operations generated $601 million in revenue, up just 2% year-over-year, driven by growth in naval propulsion and special materials programs that was partially offset by lower advanced nuclear volumes. However, adjusted EBITDA declined 5% to $126 million, with margins compressing to 21.0% from 22.6% in the prior year. Management attributed the margin pressure to higher positive contract adjustments in the comparable 2025 period and a less favorable business mix, though these headwinds were partially offset by higher technical services equity income.
By contrast, Commercial Operations delivered exceptional performance with revenue surging 72% to $303 million, including 33% organic growth. The segment benefited from broad-based strength across commercial nuclear components, field services, fuel handling, and medical operations, plus contributions from the Kinectrics acquisition. Adjusted EBITDA more than doubled to $36 million, with margins expanding to 11.9% from 9.2%, driven by higher volumes, improved business mix, and solid operational execution that more than offset SG&A investments to support future growth.
Strategic Initiatives
The quarter featured several significant strategic developments that position BWXT for long-term growth in both defense and commercial nuclear markets.
On the government side, BWXT announced contracts supporting the U.S. Naval Nuclear Propulsion Program totaling over $1.4 billion. This included a five-year, $1.3 billion long-lead material procurement contract and $165 million for procurement of long-lead reactor system components and manufacturing for the Ford-class aircraft carrier program. The company’s TRISO fuel also supported Antares Nuclear in achieving the first advanced nuclear reactor criticality milestone under the Administration’s May 2025 executive order.
In commercial markets, BWXT completed the acquisition of Precision Components Group in July 2026, marking the company’s first step in establishing a U.S. commercial nuclear component manufacturing footprint for future reactor builds and aftermarket opportunities. The company also announced the sale of its medical business for up to $800 million to Nordic Capital, allowing BWXT to sharpen its focus on core nuclear national security and commercial nuclear power markets while retaining a 20% stake in the divested business.
Additionally, BWXT licensed its mPower small modular reactor technology to Applied Atomics for land-based use and initiated a feasibility study with Core Power to explore using mPower for floating nuclear power plants, demonstrating a strategy to monetize intellectual property through licensing rather than direct commercialization.
Forward-Looking Statements
Based on strong first-half performance and an improving outlook for both segments, BWXT raised its full-year 2026 guidance across all key metrics, as detailed in the following outlook summary.
The company now expects revenue of approximately $3.80 billion, up from the prior guidance of more than $3.75 billion, representing high-teens year-over-year growth with mid-teens organic growth. Adjusted EBITDA guidance increased to $662-672 million from $650-665 million previously, reflecting mid-to-high-teens growth. Non-GAAP EPS guidance rose to $4.70-4.80 from $4.60-4.75, also representing mid-to-high-teens growth. Free cash flow guidance saw the most significant increase, rising to $345-360 million from $315-330 million.
Management expects Government Operations to deliver high-single-digit revenue growth driven primarily by new special materials programs and modest naval propulsion growth, with segment margins of approximately 20.5%. Commercial Operations is projected to grow approximately 45%, driven by mid-to-high-teens organic growth plus contributions from the Kinectrics and Precision Components Group acquisitions, with segment margins of approximately 13.0%.
The following bridge analysis shows how BWXT expects to progress from 2025’s non-GAAP EPS of $4.01 to the 2026 guidance range of $4.70-4.80.
Operational improvements are expected to contribute $0.58-0.68 to EPS growth, driven by EBITDA expansion in both Government and Commercial operations, though partially offset by higher depreciation and amortization. Significantly lower interest expense from balance sheet optimization should add approximately $0.30, while non-operational headwinds from pension and other income items will reduce EPS by roughly $0.15. A slightly higher tax rate and share count are expected to subtract approximately $0.05 combined.
Analyst Perspectives
According to the earnings article, analysts during the call focused on several key topics, including the strategic rationale for the medical business sale, integration plans for Precision Components Group, and the timing of potential new commercial nuclear equipment orders.
Management indicated that while the medical business was not actively for sale, Nordic Capital approached with an attractive offer that allows BWXT to concentrate resources on its core nuclear national security and commercial power businesses. Chief Executive Russ Jevnin told analysts the company "delivered another strong quarter characterized by excellent execution across the company and continued momentum in commercial nuclear," adding that BWXT faces the market "from a position of strength."
Regarding new commercial opportunities, Jevnin said BWXT is in active discussions with GE Vernova and Westinghouse and sees credible chances of securing at least one new reactor build order before the end of 2026. On the mPower technology, management clarified the strategy is to monetize the intellectual property through licensing and manufacturing rights rather than direct commercialization.
Chief Financial Officer Mike Fitzgerald noted that the company’s "robust backlog, expanding opportunity pipeline, strong cash generation, and continued focus on execution" are increasing confidence in 2026 and beyond. He also highlighted that commercial revenue growth guidance was lifted due to both the Precision Components Group acquisition and stronger organic demand trends.
The after-hours stock decline despite the earnings beat and raised guidance suggests some investors remain concerned about near-term margin pressure in the commercial segment as the company invests heavily in new capacity, with capital spending planned at approximately 6% of sales in 2026 and potentially closer to 7% in future years. The company plans to provide additional details on its growth investments at an Investor Day scheduled for September 2026.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.